OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
JMIB55

JMI Syringes & Medical Devices Ltd

Medical Equipment, Supplies & DistributionVerified

JMI Syringes & Medical Devices Ltd maintains a strong liquidity position, with a current ratio of 5.12, indicating that it holds significantly more current assets than current liabilities. However, the company's free cash flow is negative at -163,999,180 BDT, which suggests that capital expenditures are outpacing operating cash flow. The company's cash and equivalents amount to 51,709,180 BDT, but this is offset by long-term debt of 132,842,240 BDT, resulting in a net cash position that is negative after subtracting total debt. Profitability metrics are concerning, with a return on equity of -7.03% and a return on assets of -6.09%, both significantly below the industry median for medical equipment and supplies. The company reported a net loss of 182,495,630 BDT, despite a gross profit of 44,960,270 BDT, indicating high operating and non-operating expenses. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks. Looking ahead, the company's revenue is expected to remain under pressure, with no clear growth trajectory evident from the current financial data. The operating cash flow of 65,723,550 BDT is insufficient to cover capital expenditures of 44,436,420 BDT, which may hinder long-term growth and operational flexibility. The risk assessment indicates a medium liquidity risk, primarily due to the negative free cash flow and the net cash position being negative after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. Recent filings and transcripts do not provide additional insights into the company's strategic direction or operational performance. The company's financial health remains a concern, with a net loss and negative returns on equity and assets.

30-day price · JMIB(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyJMI Syringes & Medical Devices Ltd
TickerJMIB.DH
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. JMI Syringes & Medical Devices Ltd designs, develops, and distributes medical devices and syringes, primarily serving the healthcare sector.

Classification. The company is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

JMI Syringes & Medical Devices Ltd maintains a strong liquidity position, with a current ratio of 5.12, indicating that it holds significantly more current assets than current liabilities. However, the company's free cash flow is negative at -163,999,180 BDT, which suggests that capital expenditures are outpacing operating cash flow. The company's cash and equivalents amount to 51,709,180 BDT, but this is offset by long-term debt of 132,842,240 BDT, resulting in a net cash position that is negative after subtracting total debt. Profitability metrics are concerning, with a return on equity of -7.03% and a return on assets of -6.09%, both significantly below the industry median for medical equipment and supplies. The company reported a net loss of 182,495,630 BDT, despite a gross profit of 44,960,270 BDT, indicating high operating and non-operating expenses. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks. Looking ahead, the company's revenue is expected to remain under pressure, with no clear growth trajectory evident from the current financial data. The operating cash flow of 65,723,550 BDT is insufficient to cover capital expenditures of 44,436,420 BDT, which may hinder long-term growth and operational flexibility. The risk assessment indicates a medium liquidity risk, primarily due to the negative free cash flow and the net cash position being negative after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. Recent filings and transcripts do not provide additional insights into the company's strategic direction or operational performance. The company's financial health remains a concern, with a net loss and negative returns on equity and assets.
Key takeaways
  • JMI Syringes & Medical Devices Ltd has a strong current ratio but a negative free cash flow, indicating liquidity challenges.
  • The company's profitability is weak, with a return on equity of -7.03% and a return on assets of -6.09%.
  • Revenue is concentrated in a single business segment, increasing operational risk.
  • The company's liquidity risk is medium, and its net cash position is negative after subtracting total debt.
  • No significant dilution risk is identified, but the company's financial performance remains a concern.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyBDT
Revenue$417.0M
Gross profit$45.0M
Operating income$581.9k
Net income-$182.5M
R&D
SG&A
D&A
SBC
Operating cash flow$65.7M
CapEx-$44.4M
Free cash flow-$164.0M
Total assets$3.00B
Total liabilities$402.8M
Total equity$2.60B
Cash & equivalents$51.7M
Long-term debt$132.8M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$1.98B$217.7M$96.0M-$148.5M
FY-3$1.99B$194.8M$89.1M$34.4M
FY-2$2.44B$222.7M$100.6M$7.2M
FY-1$1.76B$74.5M-$150.0M-$120.4M
FY0$1.79B$139.9M$38.9M$96.9M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$3.32B$2.69B$28.5M
FY-3$3.12B$2.71B$45.8M
FY-2$3.42B$2.75B$91.7M
FY-1$3.00B$2.60B$51.7M
FY0$2.96B$2.60B$43.0M
PeriodOCFCapExFCFSBC
FY-4-$32.7M-$247.2M-$148.5M
FY-3$185.1M-$60.3M$34.4M
FY-2$40.8M-$97.9M$7.2M
FY-1$65.7M-$44.4M-$120.4M
FY0$122.0M-$12.7M$96.9M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$417.0M$581.9k-$182.5M-$164.0M
FQ-6$432.3M$11.5M$2.4M$18.3M
FQ-5$453.0M$21.0M$2.0M$16.6M
FQ-4$416.3M$38.6M$10.8M$25.7M
FQ-3$492.0M$68.8M$23.8M$38.2M
FQ-2$463.0M$45.8M$21.9M$37.5M
FQ-1$535.6M$53.1M$29.4M
FQ0$431.5M$14.0M-$718.8k-$12.3M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$3.00B$2.60B$51.7M
FQ-6$3.01B$2.60B$16.5M
FQ-5$2.93B$2.57B$22.2M
FQ-4$3.00B$2.58B$30.0M
FQ-3$2.96B$2.60B$43.0M
FQ-2$2.93B$2.63B$38.9M
FQ-1$3.01B$2.63B$96.5M
FQ0$3.06B$2.63B$97.1M
PeriodOCFCapExFCFSBC
FQ-7$65.7M-$44.4M-$164.0M
FQ-6$36.6M-$2.2M$18.3M
FQ-5$73.3M-$5.4M$16.6M
FQ-4$101.7M-$8.3M$25.7M
FQ-3$122.0M-$12.7M$38.2M
FQ-2$31.6M-$1.5M$37.5M
FQ-1$88.2M-$4.1M
FQ0$80.3M-$5.3M-$12.3M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$2.60B
Net cash-$81.1M
Current ratio5.1
Debt/Equity0.1
ROA-6.1%
ROE-7.0%
Cash conversion-36.0%
CapEx/Revenue-10.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricJMIBActivity
Op margin0.1%3.9% medp25 -31.3% · p75 14.4%below median
Net margin-43.8%2.4% medp25 -30.5% · p75 11.1%bottom quartile
Gross margin10.8%46.7% medp25 28.2% · p75 63.1%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-10.7%-4.8% medp25 -11.6% · p75 -2.4%below median
Debt / equity5.0%17.9% medp25 2.7% · p75 52.2%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 07:13 UTC#c3653fe9
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 06:53 UTCJob: 23c574e4